ライフサイエンスコーパス: anticancer agent

1 explored the potential of stauprimide as an anticancer agent.

2 mpound of profound interest as a prospective anticancer agent.

3 nano-oral delivery system for this promising anticancer agent.

4 dicine has gained approval as a new class of anticancer agent.

5 rol (RES) has been studied extensively as an anticancer agent.

6 a styryl benzylsulfone, is a phase III stage anticancer agent.

7 s for safer dosing of this widely prescribed anticancer agent.

8 gene under current investigation as a novel anticancer agent.

9 rest in the potential use of metformin as an anticancer agent.

10 me inhibitor with desirable properties as an anticancer agent.

11 29 that potentially strengthen its use as an anticancer agent.

12 genetic protein 4 (BMP4) has potential as an anticancer agent.

13 n demonstrated to have potent activity as an anticancer agent.

14 PC is a natural pigment with potential as an anticancer agent.

15 ing its in vivo efficacy as a potential lead anticancer agent.

16 (HCT-116 colon cancer xenograft mouse model) anticancer agent.

17 ants extensive evaluations as a new class of anticancer agent.

18 otential therapeutic use of CRLX522 as a new anticancer agent.

19 ch is an analogue of the potent indole-based anticancer agent.

20 the focus of intense research as a potential anticancer agent.

21 days after adjudication) for the index oral anticancer agent.

22 compounds represent a new potential class of anticancer agents.

23 xes have been recently investigated as novel anticancer agents.

24 soform, and this may limit their efficacy as anticancer agents.

25 eudolaric acid B (PAB) holds promise for new anticancer agents.

26 inhibitors, potential anti-inflammatory and anticancer agents.

27 able core for optimization to identify novel anticancer agents.

28 gned, synthesized and evaluated as potential anticancer agents.

29 tunity for endothelial-specific targeting of anticancer agents.

30 he development of these rigidin analogues as anticancer agents.

31 temic multi-delivery of poorly water soluble anticancer agents.

32 lysates for the early stage of apoptosis or anticancer agents.

33 as a potential target for the development of anticancer agents.

34 - and crinine-type alkaloids show promise as anticancer agents.

35 a useful structure for the generation of new anticancer agents.

36 These processes are targets of many anticancer agents.

37 of water-soluble and/or poorly water-soluble anticancer agents.

38 p G-quadruplex binders as safe and effective anticancer agents.

39 serve as companion diagnostics for targeted anticancer agents.

40 l formulations of TPT and other weakly-basic anticancer agents.

41 efficacious and nontoxic PAI-1 inhibitors as anticancer agents.

42 luable opportunities for rapid assessment of anticancer agents.

43 uinolinones was synthesized and evaluated as anticancer agents.

44 has the potential to enhance the efficacy of anticancer agents.

45 of direct Ras inhibitors as a novel class of anticancer agents.

46 ent a new class of potent microtubule-active anticancer agents.

47 on the future development of these effective anticancer agents.

48 TH1 in general as a promising novel class of anticancer agents.

49 f histone deacetylase inhibitors (HDACIs) as anticancer agents.

50 exhibit reduced Bim levels and resistance to anticancer agents.

51 a-2) increased sensitivity to platinum-based anticancer agents.

52 inhibitors are gaining interest as potential anticancer agents.

53 oping specific Cdc20 inhibitors as effective anticancer agents.

54 C), were originally and are still pursued as anticancer agents.

55 ir immunogenic capacity as novel and dynamic anticancer agents.

56 e ProTide approach to generate promising new anticancer agents.

57 opment of glutamine metabolism inhibitors as anticancer agents.

58 a response mechanism to metabolic stress and anticancer agents.

59 y of various types of therapeutics including anticancer agents.

60 with respect to the development of potential anticancer agents.

61 m of action for PEITC and other ROS-inducing anticancer agents.

62 a previously unpursued route for developing anticancer agents.

63 stress and contributes to resistance against anticancer agents.

64 nstrated mixed outcomes regarding statins as anticancer agents.

65 gy for development of specific and effective anticancer agents.

66 en prepared as a new chemotype for potential anticancer agents.

67 r sensitivities and resistance mechanisms to anticancer agents.

68 ork synergistically to create more effective anticancer agents.

69 a first step toward a new class of potential anticancer agents.

70 azones (BpT) class, show marked potential as anticancer agents.

71 us has become an attractive target for novel anticancer agents.

72 position 2 of the indole were synthesized as anticancer agents.

73 ce of targeting ERRalpha with antagonists as anticancer agents.

74 size, indicating their in vivo potential as anticancer agents.

75 tothecin and a variety of other DNA-damaging anticancer agents.

76 any type of DSB, including those induced by anticancer agents.

77 analogues have significant potential as new anticancer agents.

78 ns, often after chronic exposure to targeted anticancer agents.

79 Iron chelators have emerged as promising anticancer agents.

80 upting agents (VDAs) and as highly cytotoxic anticancer agents.

81 may be a useful lead for the development of anticancer agents.

82 s recently emerged as a promising target for anticancer agents.

83 l use or have advanced to clinical trials as anticancer agents.

84 itors, such as ABT263, as safe and effective anticancer agents.

85 he tumor cells susceptible to currently used anticancer agents.

86 are being developed as potential therapeutic anticancer agents.

87 been synthesized and evaluated as potential anticancer agents.

88 r of natural products have been advocated as anticancer agents.

89 d, MYC-WDR5 inhibitors could be developed as anticancer agents.

90 tive strategy for therapeutic development of anticancer agents.

91 enerated by TOP1 inhibitors commonly used as anticancer agents.

92 erable interest as potential chemopreventive anticancer agents.

93 cting compounds may represent novel powerful anticancer agents.

94 adjudicated prescription for any of 38 oral anticancer agents.

95 of alternate oral, injectable, or infusible anticancer agents.

96 e clinical utility in the development of new anticancer agents.

97 spliceosome-modulating activity as potential anticancer agents.

98 ms of RCC provide specific targets for novel anticancer agents.

99 Autophagy mediates resistance to various anticancer agents.

100 cumulate in DNA following treatment with the anticancer agents 5-fluorouracil and 5-fluorodeoxyuridin

101 and high drug encapsulation is desirable for anticancer agents, a mechanistic understanding is requir

102 ain permeability of two drugs, including the anticancer agent acivicin.

103 to DNA gyrase inhibition and suggests other anticancer agents act similarly.

104 they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma.

105 reversible proteasome inhibitor as potential anticancer agents against solid tumors.

106 l-asparaginase (l-ase) is an anticancer agent also harboring glutaminase activity.

107 linically employed and experimental targeted anticancer agents also mediate immunostimulatory or immu

108 Surface MHC levels can be modulated by anticancer agents, altering immunity.

109 ors (NRTIs) are widely used as antiviral and anticancer agents, although they require intracellular p

110 Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), doceta

111 s study illuminates the function of an early anticancer agent and suggests an intersection with ongoi

112 he chemotherapeutic drug Taxol, an important anticancer agent and the only known stabilizer that redu

113 NAP have been suggested as immunotherapeutic anticancer agents and adjuvants for vaccination but with

114 panion (pet) dogs, allow assessment of novel anticancer agents and combination therapies in a veterin

115 ecent research on other poorly water-soluble anticancer agents and delivery of drug combinations (i.e

116 lear metal complexes offers a route to novel anticancer agents and delivery systems.

117 ied; they are now used in ex vivo studies of anticancer agents and early detection.

118 he main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harne

119 es are nanocarriers for poorly water-soluble anticancer agents and have advanced paclitaxel (PTX) to

120 udies that have expanded CTCs for testing of anticancer agents and how these approaches might be used

121 e therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathwa

122 g the administration of different classes of anticancer agents and in all cases observed that the mod

123 hat SIRT2-selective inhibitors are promising anticancer agents and may represent a general strategy t

124 -directed intraperitoneal targeting of other anticancer agents and nanoparticles using peptides and o

125 suggest a possible use of NK-derived EVs as anticancer agents and propel the development of new stra

126 A wide spectrum of drugs, such as anticancer agents and steroids, are known P-gp substrate

127 ween the mechanisms of action of these novel anticancer agents and the imaging appearance of tumor re

128 orrelation between sensitivity to alkylating anticancer agents and topoisomerase inhibitors.

129 eful natural products such as anthelmintics, anticancer agents, and immunosuppressives.

130 her therapeutic classes (neurological drugs, anticancer agents, and many others), can prolong the QT

131 ally important antibiotics, antifungals, and anticancer agents are actually present in the soils of N

132 oside phosphonates as potential antiviral or anticancer agents are compiled.

133 These novel anticancer agents are critically discussed by the author

134 e syntheses of tetrasubstituted olefin-based anticancer agents are described.

135 ith conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecu

136 Moreover, because the latest generations of anticancer agents are founded on biological mechanisms,

137 g outstanding properties as antimicrobial or anticancer agents, are still in early stages of assessme

138 , providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeu

139 ll most probably emerge for newly discovered anticancer agents as well.

140 enal transplantation, and of rapamycin as an anticancer agent, as well as from experimental studies.

141 d with paclitaxel, a microtubule-stabilizing anticancer agent, as well as with 6-coumarin, a fluoresc

142 er herpesviruses, and (ii) be developed into anticancer agents, as functions of KAP1 and ATM are tigh

143 designed and synthesized to co-deliver three anticancer agents, AS1411, doxorubicin and anti-221, for

144 While demonstrated to be effective anticancer agents, B-Raf or MEK inhibitors have also bee

145 Anticancer agents based on haloacetic acids are develope

146 new 2-phenylindole derivatives as potential anticancer agents bearing the 3,4,5-trimethoxyphenyl moi

147 as promising probes of DNA structure and as anticancer agents because of their unique photophysical

148 ell death makes CDD a potentially attractive anticancer agent, because tumor resistance to the main m

149 vance to a broad spectrum of next-generation anticancer agents being developed by the medicinal inorg

150 Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patie

151 have demonstrated or predicted potential as anticancer agents, but a detailed structural basis for t

152 proliferation and is inhibited by promising anticancer agents, but its mode of action and the conseq

153 s predictive of sensitivity or resistance to anticancer agents, but the identification of actionable

154 The anticancer agent camptothecin (CPT) is a DNA topoisomera

155 m, where the biologic effects of traditional anticancer agents can be delineated, prognostic and pred

156 n drug-mediated anticancer activity and that anticancer agents can be identified through their abilit

157 Despite the discovery of a large number of anticancer agents, cancer still remains among the leadin

158 Thus, novel anticancer agents capable of overcoming these intrinsic

159 sive efforts to target mutated RAS proteins, anticancer agents capable of selectively killing tumour

160 Strain-dependent delivery of the anticancer agents cisplatin and 7-ethyl-10-hydroxycampto

161 The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplati

162 ular mechanism of a potent platinum-acridine anticancer agent (compound 1), a correlation analysis of

163 ed for a set of rigidified platinum-acridine anticancer agents containing linkers derived from chiral

164 Its documented success as an anticancer agent, coupled with early concerns over suppl

165 Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduc

166 tecan (LMP400) and indimitecan (LMP776), two anticancer agents currently under investigation in a Pha

167 Phenanthriplatin, a monofunctional anticancer agent derived from cisplatin, shows significa

168 future development of additional efficacious anticancer agents derived from natural products.

169 ed approaches for discovering and developing anticancer agents designed specifically to prevent or de

170 and cancer and also suggest the potential of anticancer agents designed to specifically neutralize ex

171 first representative of this novel class of anticancer agents, displays a superior activity profile

172 years, with the development of numerous oral anticancer agents, dosing options are arbitrarily and in

173 rodent protoparvoviruses (PVs) are promising anticancer agents due to their excellent safety profile,

174 -dimethoxyflavone) has great potential as an anticancer agent, due to its specific chemopreventive ac

175 II) (cis-DDP)] is one of the most successful anticancer agents effective against a wide range of soli

176 H-1 covalently conjugated with anthracycline anticancer agent, epirubicin, integrates the advantages

177 clinical translation of poorly water-soluble anticancer agents, especially for promising, rapidly eme

178 enium complexes are promising candidates for anticancer agents, especially NKP-1339 (sodium trans-[te

179 termini, and renders cells sensitive to the anticancer agent etoposide.

180 DF15) in glioblastoma cells treated with the anticancer agent fenofibrate.

181 Anticancer agent FL118 was recently identified in screen

182 t are currently under development for use as anticancer agents following the FDA approval of two HDAC

183 of EGFR protein abundance and as a potential anticancer agent for aneuploidy-driven colorectal cancer

184 nd it can act as a promising antioxidant and anticancer agent for future applications in pharmaceutic

185 ptide has potential to be developed as a new anticancer agent for intratumoral administration and is

186 cancers and that MLN4924 may be an effective anticancer agent for targeted ovarian cancer therapy.

187 inogenesis and its inhibition in sensitizing anticancer agents for killing of cancer cells.

188 We screened 31 anticancer agents for their ability to decrease cell via

189 in situ generation of a triazole-containing anticancer agent from two benign components, opening up

190 reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synt

191 ulation of low-toxicity molecularly targeted anticancer agents has been limited.

192 The high market price of new anticancer agents has stimulated debate about the long-t

193 -arylpyrrole (ARAP) derivatives as potential anticancer agents having different substituents at the p

194 drug conjugates hold considerable promise as anticancer agents, however, producing them remains a cha

195 These efforts include screening for novel anticancer agents, identifying novel therapeutic targets

196 ormin is currently considered as a promising anticancer agent in addition to its anti-diabetic effect

197 tion in vitro and in vivo and an efficacious anticancer agent in animal models of human cancers.

198 However, it also acts as a weak anticancer agent in certain in vivo models through a mec

199 e kinase, has been demonstrated to act as an anticancer agent in several cancer cell types.

200 ze isoanabasine, preclamol, and niraparib-an anticancer agent in several clinical trials.

201 ltransferase Porcupine (Porcn) are candidate anticancer agents in clinical testing.

202 al indenoisoquinolines have shown promise as anticancer agents in clinical trials.

203 revent client maturation and show promise as anticancer agents in clinical trials.

204 otropic autophagy inhibitors may have use as anticancer agents in combination with conventional thera

205 The enhanced activity of these anticancer agents in combination with p28 was facilitate

206 ic sources served as potential antiviral and anticancer agents in the past.

207 ities of established drugs and other rhenium anticancer agents in the TRIP-resistant cell line were d

208 e the therapeutic indices of different class anticancer agents in vivo.

209 iety of combinations of different classes of anticancer agents including small molecule drugs and bio

210 ollowing exposure to several stress-inducing anticancer agents, including ionizing radiation (IR), et

211 tion of Rac hyperactivation to resistance to anticancer agents, including targeted therapies, as well

212 bocyclic analogues of an important series of anticancer agents inhibiting MDM2-p53 interactions.

213 he maximum tolerated dose of investigational anticancer agents is based on the cytotoxic chemotherapy

214 yrolactone analogues and their evaluation as anticancer agents is described.

215 Purpose The number of novel oral anticancer agents is increasing, but financial barriers

216 of HOTAIR in pancreatic cancer resistance to anticancer agents is unknown.

217 Although TRAIL is considered a potential anticancer agent, it enhances tumor progression by activ

218 ones with camptothecin (CPT), a largely used anticancer agent, KuQs have been tested against Cisplati

219 ring resistance to many structurally diverse anticancer agents, leading to the phenomenon called mult

220 the microtubule lattice and is inhibited by anticancer agents like Taxol.

221 than one bioactive moiety in a multitargeted anticancer agent may result in synergistic activity of i

222 he real-world clinical effectiveness of oral anticancer agents may be diminished and may not emulate

223 ests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as

224 a (PDA) cells by treatment with DNA-damaging anticancer agents (mitomycin C, oxaliplatin, cisplatin,

225 g lead for further development to obtain new anticancer agents of potential value for the treatment o

226 Anticancer agents often cause drug-induced tetraploidy (

227 ly apparent that treatment with a variety of anticancer agents often is associated with adverse neuro

228 al proof of concept for a survivin-targeting anticancer agent, our work offers novel in silico screen

229 re is a steady increase in costs of patented anticancer agents over time.

230 insoluble drugs including the developmental anticancer agent PBS-1086.

231 omprehensive conformational analysis for the anticancer agent pironetin (1) was achieved by molecular

232 reticulum (ER) stress, as also found for the anticancer agent PRIMA-1(MET)(APR-246).

233 received much attention as immunotherapeutic anticancer agents since the discovery that they harbor f

234 omatitis virus (VSV) are being considered as anticancer agents since they readily infect transformed

235 ivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat

236 nes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib

237 Reactive oxygen species (ROS)-inducing anticancer agents such as phenethylisothiocyanate (PEITC

238 is in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263

239 poptosis and resistance to multiple types of anticancer agents suggests the potential to improve comb

240 lication to the efficient preparation of the anticancer agent (+)-tangutorine.

241 16 may be developed as a safe first-in-class anticancer agent targeting BCL-X(L).

242 iaryl (biaryl-benzenesulfonamides) as potent anticancer agents targeting both STAT3 and tubulin.

243 was illustrated by the short synthesis of an anticancer agent, TEI-9826.

244 sensitize cells to irradiation or to several anticancer agents tested.

245 moreover, these compounds are more effective anticancer agents than their sulfur isosteres.

246 his study, we present a small-molecule-based anticancer agent that acts by inhibiting dimerization of

247 ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptos

248 CPI-613 is a novel anticancer agent that selectively targets the altered fo

249 e a synergistic effect with methotrexate, an anticancer agent that targets purine biosynthesis.

250 o-integrin (integrin alphavbeta3) antagonist anticancer agent that works via genetic and nongenetic a

251 ted their potential as promising theranostic anticancer agents that can circumvent cisplatin resistan

252 hes an integrated approach for testing novel anticancer agents that captures the inherent variability

253 w summarizes previous studies on metal-based anticancer agents that cause ER stress.

254 a possible new route for the development of anticancer agents that could suppress KRAS expression.

255 be considered a new class of zinc-chelating anticancer agents that deserves further development.

256 Several anticancer agents that form DNA adducts in the minor gro

257 we discovered a new class of small molecule anticancer agents that has no effect on tubulin but inst

258 cs have facilitated the development of novel anticancer agents that have decreased side effects and i

259 Recombinant immunotoxins (RITs) are potent anticancer agents that have produced many complete remis

260 Notably, unlike other anticancer agents that inhibit VEGF receptor signaling,

261 t the 7-azaindenoisoquinolines are promising anticancer agents that merit further development.

262 ere, we describe new synthetic polymer-based anticancer agents that mimic the mode of action of antic

263 r therapies involve the systemic delivery of anticancer agents that neither discriminate between canc

264 se II (TOP2) poisons are effective cytotoxic anticancer agents that stabilize the normally transient

265 nia is a major side effect of a new class of anticancer agents that target histone deacetylase (HDAC)

266 Currently, there are no anticancer agents that target IRS1/2.

267 For two thirds of FDA approvals of anticancer agents, the requirement for predictive biomar

268 Due to the success of the platinum anticancer agents, there has been considerable interest

269 hesis of mycothiazole, a naturally occurring anticancer agent through a sequence that contains a long

270 nts a potent strategy for using conventional anticancer agents to alter the tumor microenvironment an

271 The inability of anticancer agents to cross the blood-brain-barrier repre

272 barrier (BBB) prevents the transport of most anticancer agents to the central nervous system and rest

273 activation suppresses the proliferation and anticancer agent tolerance of HCC.

274 to monitor liposomal release kinetics of the anticancer agent topotecan (TPT) in physiological fluids

275 pes for anthracycline and taxane, two common anticancer agents use in clinics.

276 etic precursor to the clinically significant anticancer agents vinblastine and vincristine.

277 of specialized metabolites that includes the anticancer agent vincristine, antimalarial quinine and n

278 Based on similarities to polyether anticancer agents we have further examined TDA's cytotox

279 eeper mechanistic insight into these rhenium anticancer agents, we developed and characterized an ova

280 rspective of using HTyr-derived compounds as anticancer agents, we have taken into account only studi

281 ng pursuit of CXCR4 antagonists as potential anticancer agents, we recently developed a potent, selec

282 ese cells, for the first time, two different anticancer agents were synthesized simultaneously intrac

283 n-1,12-dien-30-oate (CF(3)DODA-Me), a potent anticancer agent, were studied on cancer-lymphatic inter

284 cisplatin as the drug, since it is a potent anticancer agent which exhibits serious side effects due

285 nine, thereby providing strong resistance to anticancer agents which alkylate this position.

286 g conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial devel

287 that serves both as an anti-inflammatory and anticancer agent, which differentially affects MDSC acti

288 es to use the toxin as a potent pH-selective anticancer agent, which predominantly targets highly pro

289 5-Fluorouracil (5-FU) is an anticancer agent whose main side effects include intesti

290 a (TOP2alpha/170) is an important target for anticancer agents whose efficacy is often attenuated by

291 and complications associated with the novel anticancer agents will be summarized, since these are fr

292 further investigation as a novel preclinical anticancer agent with application in the treatment of nu

293 Acylfulvenes are a class of experimental anticancer agents with a unique repair profile suggestin

294 of 7-azaindenoisoquinolines resulted in new anticancer agents with improved Top1 inhibitory potencie

295 II) complexes are a novel class of promising anticancer agents with potential clinical significance.

296 ase I (Top1) inhibitors are a novel class of anticancer agents with two compounds in clinical trials.

297 any alternate oral, injectable, or infusible anticancer agent within 90 days.

298 eered MSCs loaded with high concentration of anticancer agents without affecting their tumor-targetin

299 Taken together, TL-77 represents a promising anticancer agent worthy of further evaluation.

300 The clinical usefulness of these anticancer agents would be substantially augmented if AG